Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The ketogenic diet as a treatment paradigm for diverse neurological disorders.
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis.
Microbial colonization influences early B-lineage development in the gut lamina propria.
Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
Corticosteroids for treating optic neuritis.
Unraveling the secrets of white matter - Bridging the gap between cellular, animal and human imaging studies.
Society for Neuroscience Annual Meeting
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Using experimental autoimmune encephalomyelitis as a model to study the effect of prenatal stress on fetal programming.
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
Olive oil phenols and neuroprotection.
American Academy of Neurology Annual Meeting
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.
Materials for stem cell factories of the future.
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
In vivo evidence of glutamate toxicity in multiple sclerosis.
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.

Pages